Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.53 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742422 | 1.00 | NLRP3 (0.54) | NLRP3PTPN1DUSP22PTPN22MEN1 | |
| SCHEMBL20339633 | 0.86 | PTPN1 (0.71) | NLRP3PTPN1DUSP22PTPN22MEN1 | |
| SCHEMBL20339632 | 0.86 | PTPN1 (0.71) | NLRP3PTPN1DUSP22PTPN22MEN1 | |
| SCHEMBL12177374 | 0.76 | PTPN1 (0.61) | NLRP3PTPN1DUSP22PTPN22 | |
| SCHEMBL13056341 | 0.75 | PTPN22 (0.70) | PTPN1PTPN22MEN1KMT2APOLB | |
| SCHEMBL1901689 | 0.74 | PTPN22 (0.61) | PTPN1PTPN22MEN1KMT2APOLB | |
| SCHEMBL1901690 | 0.74 | PTPN22 (0.61) | PTPN1PTPN22MEN1KMT2APOLB | |
| SCHEMBL1901692 | 0.74 | PTPN22 (0.61) | PTPN1PTPN22MEN1KMT2APOLB | |
| SCHEMBL6791506 | 0.73 | FFAR1 (0.65) | MEN1KMT2APOLBMAPTTDP1 | |
| SCHEMBL3135714 | 0.72 | TNFRSF1A (0.57) | PTPN1PTPN22MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | PLD2, PLD1, PLA2G2D | NLRP3 255/4885PTPN1 1175/4885DUSP22 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.